In certain situations, CDC also recommends other children and adults get meningococcal vaccines. Below is more information about which meningococcal vaccines, including booster shots, CDC recommends for people by age.
Teens may also get a MenB vaccine , preferably at 16 through 18 years old. Even if you received meningococcal vaccines, you could still get meningococcal disease.
While any teen may choose to get a MenB vaccine, certain preteens and teens should get it if they:. Meningococcal Vaccines for Preteens and Teens pdf icon [1 page] This fact sheet answers general questions about meningococcal vaccines for preteens and teens. Get more information about meningococcal vaccine recommendations for teenagers: Meningococcal Vaccination for Preteens and Teens: Information for Parents.
Because of age or health conditions, some people should not get certain vaccines or should wait before getting them. Tell the person who is giving you or your child a meningococcal vaccine if:. This immune response suggests the vaccines provide protection, but data are limited on how well they work. Since meningococcal disease is uncommon, many people need to get these vaccines in order to measure their effectiveness. Getting the year-old MenACWY booster dose is critical so teens have protection when they are most at risk for meningococcal disease.
Image Library. Screening for Contraindications. Vaccinating Adults Guide. Translations Index. English-language VISs. Spanish-language VISs. What's New: VISs. Hepatitis A. Hepatitis B. Varicella chickenpox. Zoster shingles. View All. Religious Concerns. Alternative Medicine. Responding to Parents. Alternative Schedules. Too Many Vaccines? Importance of Vaccines.
Vaccine Safety. MMR Vaccine. IAC Home. Meningococcal B. Ask the Experts Home. Billing and Reimbursement. Combination Vaccines. Contraindications and Precautions. Meningococcal ACWY. Travel Vaccines. Disease Issues. For People with Risk Factors. Booster Doses. Vaccine Storage and Handling.
Please tell us about meningococcal disease. The following groups are at increased risk for all meningococcal serogroups:. People with persistent genetic complement component deficiencies a type of immune system disorder. People who use complement inhibitors such as eculizumab Soliris, Alexion Pharmaceuticals and ravulizumab Ultomiris, Alexion Pharmaceuticals for treatment of atypical hemolytic uremic syndrome or paroxysmal nocturnal hemoglobinuria. People with anatomic or functional asplenia.
Microbiologists routinely exposed to meningococcal isolates in a laboratory. People at increased risk during an outbreak of meningococcal disease. Military recruits. College students. People living with HIV. Men who have sex with men MSM. Travelers to countries where meningococcal disease is endemic or hyperendemic, such as the meningitis belt of sub-Saharan Africa. Back to top. What meningococcal vaccines are available in the United States?
Trade Name. Type of Vaccine. Year Licensed. Approved Ages. Where can I find the most current meningococcal vaccine recommendations? MenB is routinely recommended for these groups:. People age 10 years and older who have functional or anatomic asplenia including sickle cell disease. People age 10 years and older who have persistent complement component deficiency an immune system disorder or who take a complement inhibitor such as eculizumab Soliris, Alexion Pharmaceuticals or ravulizumab Ultomiris, Alexion Pharmaceuticals.
People age 10 years and older who are exposed during an outbreak caused by serogroup B. Microbiologists who work with meningococcal isolates in a laboratory. For adolescents and young adults not otherwise at increased risk for meningococcal B disease, ACIP recommends that a MenB series may be administered to people 16 through 23 years of age preferred age 16 through 18 years on the basis of shared clinical decision-making.
To assist with the shared clinical decision-making around the option to vaccinate against meningococcal serogroup B disease and the timing of vaccination, CDC has provided some specific considerations about the disease and the vaccine that the patient and provider may weigh:. Serious nature of invasive meningococcal serogroup B infection, with a high risk of death and permanent complications.
Low level of serogroup B disease in the United States, with an average of 34 cases each year among people age 16 through 23 years between and Increased risk among college students, especially those who are freshmen, attending a 4-year university, living in on-campus housing, or participating in sorority and fraternity life. Protection of MenB vaccine against most strains of meningococcal serogroup B bacteria. Evidence to date suggests no impact of MenB vaccine on meningococcal B carriage may protect an individual from invasive disease but is unlikely to impact transmission of the bacteria to others.
Do any of the bacterial vaccines that are recommended for people with functional or anatomic asplenia need to be given before splenectomy? Which groups should receive a booster dose of MenB? Booster doses should be administered to people in the following groups as long as increased risk remains:. People with functional or anatomic asplenia, including sickle cell disease.
People with persistent complement component deficiency an immune system disorder. People who take a complement inhibitor eculizumab [Soliris] or ravulizumab [Ultomiris]. Microbiologists who routinely work with meningococcal isolates. Previously vaccinated people who are at risk during a meningococcal B disease outbreak. Administering Vaccine. By what route should meningococcal vaccines be administered? What adverse events are expected after receiving MenB?
Vaccines and Preventable Diseases. Section Navigation. Facebook Twitter LinkedIn Syndicate. Minus Related Pages. The risk for meningitis infections increases among teens and college students, in part because these groups spend so much time in close quarters, easily exposing one another to infectious agents.
For many years, the meningitis vaccine used for teens was the MPSV4, or polysaccharide meningococcal vaccine. A new meningitis vaccine, the MCV4, or meningococcal conjugate vaccine , was approved in It is recommended for use in children over age 2 and in young adults, and is now usually given to kids at their or year-old check up, unless they needed to be vaccinated sooner.
Studies comparing the two meningitis vaccines have shown that the older MPSV4 vaccine does not create a lasting immunity the way that the newer MCV4 appears to, which is why the CDC now recommends that young adults who were vaccinated using MPSV4 over five years ago and are still living in college dormitory-type situations, including military service, should get revaccinated with the newer vaccine, MCV4.
MPSV4 is still preferred for adults over However, college students living in dorms who have already had the newer vaccine do not need to get a booster.
0コメント